










































FAITH Investigators and HEALTH Investigators
(J Orthop Trauma 2020;34:Sii–Siii)
SUPPLEMENT STUDY SUMMARIES
This supplement titled, “Outcomes After Hip Fractures:
Secondary Analyses From the HEALTH and FAITH Trials”
includes the manuscripts for 12 preplanned secondary analy-
ses that use data from 2 large multicenter randomized
controlled trials of older hip fracture patients. Please see
below for a summary of each trial and their findings.
FAITH STUDY OVERVIEW
The FAITH (fracture fixation in the operative manage-
ment of hip fractures) trial was a multicenter randomized
controlled trial comparing the intervention of cancellous screws
with a sliding hip screw in 1079 patients 50 years of age or older
with a low energy displaced or undisplaced femoral neck
fracture. Patients were enrolled from 81 clinical sites in the
United States, Canada, Australia, the Netherlands, Norway,
Germany, the United Kingdom, and India and were assessed
clinically at 1 and 10 weeks and 6, 9, 12, 18, and 24 months
postsurgery. The primary outcome of the FAITH trial was
unplanned revision surgery within 24 months of femoral neck
fracture to promote fracture healing, relieve pain, treat infection,
or improve function. The secondary outcomes were to determine
the impact of a sliding hip screw versus cancellous screws on
health-related quality of life, functional outcomes, health state
utilities, fracture healing, mortality, and other adverse events,
such as avascular necrosis, nonunion, malunion, implant
breakage or failure, and infection.1 Unplanned revision surgery
within 24 months did not differ by type of surgical fixation as
follows: 107 of 542 patients (20%) in the sliding hip screw
group versus 117 of 537 patients (22%) in the cancellous screws
group (hazard ratio [HR] 0.83, 95% confidence interval [CI]
0.63–1.09; P = 0.18). Health-related quality of life, functional
outcomes, health state utilities, fracture healing, and mortality
also did not differ between groups (P. 0.05). Avascular necro-
sis was more common in the sliding hip screw group as com-
pared to the cancellous screws group (HR 1.91, 1.06–3.44; P =
0.0319). However, no significant difference was found between
the number of medically related adverse events between groups
(P = 0.82).2 The FAITH trial was registered on ClinicalTrials.
gov (NCT00761813) and approved by the Hamilton Integrated
Research Ethics Board (#06-402) as well as by all participating
clinical sites’ Research Ethics Boards/Institutional Review
Boards. The protocol has been previously published1 as well
as the primary study results.2
HEALTH STUDY OVERVIEW
The HEALTH (hip fracture evaluations with alternatives
of total hip arthroplasty vs. hemiarthroplasty) trial was a 1441-
patient multicenter randomized controlled trial comparing the
intervention of total hip arthroplasty with hemiarthroplasty in
patients 50 years of age or older with low energy displaced
femoral neck fractures. Patients were enrolled from 80 clinical
sites in the United States, Canada, Australia, New Zealand,
Finland, the Netherlands, Norway, Spain, the United Kingdom,
and South Africa. The primary outcome was unplanned revision
surgery within 24 months of the femoral neck fracture.
Secondary outcomes included death, serious adverse events,
hip-related complications, health-related quality of life, function,
and overall health end points.3 Unplanned revision surgery
within 24 months did not differ between treatment groups as
follows: 57 of 718 patients (7.9%) who had been randomly
assigned to total hip arthroplasty versus 60 of 723 patients
(8.3%) who had been randomly assigned to hemiarthroplasty
(HR 0.95, 95% CI 0.64–1.40; P = 0.79). Hip instability or
dislocation occurred in 34 patients (4.7%) assigned to total hip
arthroplasty and 17 patients (2.4%) assigned to hemiarthroplasty
(HR, 2.00; 99% CI, 0.97–4.09). Function, as measured with the
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total Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) total score, pain score, stiffness score, and
function score, modestly favored total hip arthroplasty over hem-
iarthroplasty. Death and serious adverse events were similar
between groups (P . 0.05).4 The trial was registered on
ClinicalTrials.gov (NCT00556842) and approved by the
Hamilton Integrated Research Ethics Board (#06-151) as well
as by all participating clinical sites’ Research Ethics
Boards/Institutional Review Boards. The protocol has been pre-
viously published3 as well as the primary study results.4
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